相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Combinatorial strategies for combating invasive fungal infections
Michaela Spitzer et al.
VIRULENCE (2017)
Phase 3 pharmacokinetics and safety study of a posaconazole tablet formulation in patients at risk for invasive fungal disease
Oliver A. Cornely et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2016)
Initial use of combination treatment does not impact survival of 106 patients with haematologic malignancies and mucormycosis: a propensity score analysis
A. Kyvernitakis et al.
CLINICAL MICROBIOLOGY AND INFECTION (2016)
Antifungal Agents Spectrum of Activity, Pharmacology, and Clinical Indications
Jeniel E. Nett et al.
INFECTIOUS DISEASE CLINICS OF NORTH AMERICA (2016)
Utility of voriconazole therapeutic drug monitoring: a meta-analysis
Me-Linh Luong et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2016)
Comparison of posaconazole serum concentrations from haematological cancer patients on posaconazole tablet and oral suspension for treatment and prevention of invasive fungal infections
Aaron N. Pham et al.
MYCOSES (2016)
Emerging Threats in Antifungal-Resistant Fungal Pathogens
Dominique Sanglard
FRONTIERS IN MEDICINE (2016)
Therapeutic drug monitoring in the treatment of invasive aspergillosis with voriconazole in cancer patients-an evidence-based approach
Meinolf Karthaus et al.
ANNALS OF HEMATOLOGY (2015)
Combination Antifungal Therapy for Invasive Aspergillosis A Randomized Trial
Kieren A. Marr et al.
ANNALS OF INTERNAL MEDICINE (2015)
Isavuconazole: A New Option for the Management of Invasive Fungal Infections
Natasha N. Pettit et al.
ANNALS OF PHARMACOTHERAPY (2015)
Mechanisms of echinocandin antifungal drug resistance
David S. Perlin
ANTIMICROBIAL THERAPEUTICS REVIEWS (2015)
Retrospective Comparison of Posaconazole Levels in Patients Taking the Delayed-Release Tablet versus the Oral Suspension
Urshila Durani et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)
Efficacy of the Clinical Agent VT-1161 against Fluconazole-Sensitive and -Resistant Candida albicans in a Murine Model of Vaginal Candidiasis
E. P. Garvey et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)
Superior Serum Concentrations with Posaconazole Delayed-Release Tablets Compared to Suspension Formulation in Hematological Malignancies
Aaron Cumpston et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)
Antifungal Activities of SCY-078 (MK-3118) and Standard Antifungal Agents against Clinical Non-Aspergillus Mold Isolates
Frederic Lamoth et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)
Isavuconazole: A New Broad-Spectrum Triazole Antifungal Agent
Marisa H. Miceli et al.
CLINICAL INFECTIOUS DISEASES (2015)
Isavuconazole, micafungin, and 8 comparator antifungal agents' susceptibility profiles for common and uncommon opportunistic fungi collected in 2013: temporal analysis of antifungal drug resistance using CLSI species-specific clinical breakpoints and proposed epidemiological cutoff values
M. A. Pfaller et al.
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE (2015)
Posaconazole: A Review of the Gastro-Resistant Tablet and Intravenous Solution in Invasive Fungal Infections
Kate McKeage
DRUGS (2015)
The 'cephalosporin era' of triazole therapy: isavuconazole, a welcomed newcomer for the treatment of invasive fungal infections
Maria N. Chitasombat et al.
EXPERT OPINION ON PHARMACOTHERAPY (2015)
Therapeutic strategies for invasive fungal infections in neonatal and pediatric patients: an update
Zoi-Dorothea Pana et al.
EXPERT OPINION ON PHARMACOTHERAPY (2015)
Impact of special patient populations on the pharmacokinetics of echinocandins
Eline W. Muilwijk et al.
EXPERT REVIEW OF ANTI-INFECTIVE THERAPY (2015)
Azole antifungals: 35 years of invasive fungal infection management
David Allen et al.
EXPERT REVIEW OF ANTI-INFECTIVE THERAPY (2015)
Toward improved anti-cryptococcal drugs: Novel molecules and repurposed drugs
Damian J. Krysan
FUNGAL GENETICS AND BIOLOGY (2015)
Clinical experience of the use of voriconazole, caspofungin or the combination in primary and salvage therapy of invasive aspergillosis in haematological malignancies
Issam I. Raad et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2015)
Nontoxic antimicrobials that evade drug resistance
Stephen A. Davis et al.
NATURE CHEMICAL BIOLOGY (2015)
Evolutionary consequences of drug resistance: shared principles across diverse targets and organisms
Diarmaid Hughes et al.
NATURE REVIEWS GENETICS (2015)
Isavuconazole: Pharmacology, Pharmacodynamics, and Current Clinical Experience with a New Triazole Antifungal Agent
Jeffrey M. Rybak et al.
PHARMACOTHERAPY (2015)
Subtherapeutic Posaconazole Exposure and Treatment Outcome in Patients With Invasive Fungal Disease
Kim C. M. van der Elst et al.
THERAPEUTIC DRUG MONITORING (2015)
Voriconazole therapeutic drug monitoring: results of a prematurely discontinued randomized multicenter trial
D. Neofytos et al.
TRANSPLANT INFECTIOUS DISEASE (2015)
Pharmacodynamic Target Evaluation of a Novel Oral Glucan Synthase Inhibitor, SCY-078 (MK-3118), Using an In Vivo Murine Invasive Candidiasis Model
Alexander J. Lepak et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)
Drug safety assessment of oral formulations of ketoconazole
Aditya K. Gupta et al.
EXPERT OPINION ON DRUG SAFETY (2015)
Isavuconazole, a broad-spectrum triazole for the treatment of systemic fungal diseases
Seyedmojtaba Seyedmousavi et al.
EXPERT REVIEW OF ANTI-INFECTIVE THERAPY (2015)
Repurposing Drugs in Oncology (ReDO)-itraconazole as an anti-cancer agent
Pan Pantziarka et al.
ECANCERMEDICALSCIENCE (2015)
Update on Antifungal Drug Resistance
David S. Perlin et al.
CURRENT CLINICAL MICROBIOLOGY REPORTS (2015)
In Vitro Study of Sequential Fluconazole and Caspofungin Treatment against Candida albicans Biofilms
Semanti Sarkar et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2014)
Enfumafungin Derivative MK-3118 Shows Increased In Vitro Potency against Clinical Echinocandin-Resistant Candida Species and Aspergillus Species Isolates
Cristina Jimenez-Ortigosa et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2014)
Phase 1B Study of the Pharmacokinetics and Safety of Posaconazole Intravenous Solution in Patients at Risk for Invasive Fungal Disease
Johan Maertens et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2014)
The Clinical Candidate VT-1161 Is a Highly Potent Inhibitor of Candida albicans CYP51 but Fails To Bind the Human Enzyme
A. G. S. Warrilow et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2014)
Update on Epidemiology of and Preventive Strategies for Invasive Fungal Infections in Cancer Patients
John R. Perfect et al.
CLINICAL INFECTIOUS DISEASES (2014)
Recent progress in the study of the interactions of amphotericin B with cholesterol and ergosterol in lipid environments
Daniel Michal Kaminski
EUROPEAN BIOPHYSICS JOURNAL WITH BIOPHYSICS LETTERS (2014)
Cardiac toxicity of some echinocandin antifungals
Kayla R. Stover et al.
EXPERT OPINION ON DRUG SAFETY (2014)
Pharmacokinetic profile of micafungin when co-administered with amphotericin B in healthy male subjects
Nasrullah A. Undre et al.
INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS (2014)
Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology
H. Ruth Ashbee et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2014)
Liver Injury Associated With Ketoconazole: Review of the Published Evidence
H. Karl Greenblatt et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2014)
Antifungal Drug Development: Challenges, Unmet Clinical Needs, and New Approaches
Terry Roemer et al.
COLD SPRING HARBOR PERSPECTIVES IN MEDICINE (2014)
Voriconazole Therapeutic Drug Monitoring
Zachary Hoy et al.
JOURNAL OF THE PEDIATRIC INFECTIOUS DISEASES SOCIETY (2014)
Vertebral infection with Candida albicans failing caspofungin and fluconazole combination therapy but successfully treated with high dose liposomal amphotericin B and flucytosine
Line Storm et al.
MEDICAL MYCOLOGY CASE REPORTS (2014)
Voriconazole associated torsades de pointes in two adult patients with haematological malignancies
Jeremy D. Brown et al.
MEDICAL MYCOLOGY CASE REPORTS (2014)
Interactions Between Anti-Infective Agents and Immunosuppressants in Solid Organ Transplantation
J. Trofe-Clark et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2013)
Treatment of Pediatric Refractory Coccidioidomycosis With Combination Voriconazole and Caspofungin: A Retrospective Case Series
Emily R. Levy et al.
CLINICAL INFECTIOUS DISEASES (2013)
Mucormycosis treated with posaconazole: review of 96 case reports
Joerg J. Vehreschild et al.
CRITICAL REVIEWS IN MICROBIOLOGY (2013)
Optimizing antifungal choice and administration
David Andes
CURRENT MEDICAL RESEARCH AND OPINION (2013)
Azole resistance in Aspergillus fumigatus: a growing public health concern
Edith Vermeulen et al.
CURRENT OPINION IN INFECTIOUS DISEASES (2013)
Nephrotoxicity and other adverse events among inpatients receiving liposomal amphotericin B or amphotericin B lipid complex
Rolin L. Wade et al.
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE (2013)
Breakpoints for antifungal agents: An update from EUCAST focussing on echinocandins against Candida spp. and triazoles against Aspergillus spp.
Maiken C. Arendrup et al.
DRUG RESISTANCE UPDATES (2013)
Amphotericin B Formulations: A Comparative Review of Efficacy and Toxicity
Richard J. Hamill
DRUGS (2013)
In Vitro Activities of Isavuconazole and Comparator Antifungal Agents Tested against a Global Collection of Opportunistic Yeasts and Molds
Michael A. Pfaller et al.
JOURNAL OF CLINICAL MICROBIOLOGY (2013)
A severe case of haemodynamic instability during anidulafungin administration
M. Fink et al.
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS (2013)
C2′-OH of Amphotericin B Plays an Important Role in Binding the Primary Sterol of Human Cells but Not Yeast Cells
Brandon C. Wilcock et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2013)
Incidence and outcome of early Candida peritonitis after liver and pancreas transplantation
Michele Bartoletti et al.
MYCOSES (2013)
Efficiently Killing a Sugar-Coated Yeast
John R. Perfect
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Combination Antifungal Therapy for Cryptococcal Meningitis
Jeremy N. Day et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Antifungal Drug Resistance: Mechanisms, Epidemiology, and Consequences for Treatment
Michael A. Pfaller
AMERICAN JOURNAL OF MEDICINE (2012)
Multicenter Study of Posaconazole Therapeutic Drug Monitoring: Exposure-Response Relationship and Factors Affecting Concentration
Michael J. Dolton et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2012)
Posaconazole Exposure-Response Relationship: Evaluating the Utility of Therapeutic Drug Monitoring
Michael J. Dolton et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2012)
Successful treatment of rhino-orbital mucormycosis by a new combination therapy with liposomal amphotericin B and micafungin
Takao Ogawa et al.
AURIS NASUS LARYNX (2012)
Comparison of the Early Fungicidal Activity of High-Dose Fluconazole, Voriconazole, and Flucytosine as Second-Line Drugs Given in Combination With Amphotericin B for the Treatment of HIV-Associated Cryptococcal Meningitis
Angela Loyse et al.
CLINICAL INFECTIOUS DISEASES (2012)
The Effect of Therapeutic Drug Monitoring on Safety and Efficacy of Voriconazole in Invasive Fungal Infections: A Randomized Controlled Trial
Wan Beom Park et al.
CLINICAL INFECTIOUS DISEASES (2012)
Impact of Treatment Strategy on Outcomes in Patients with Candidemia and Other Forms of Invasive Candidiasis: A Patient-Level Quantitative Review of Randomized Trials
David R. Andes et al.
CLINICAL INFECTIOUS DISEASES (2012)
Evaluation of the pharmacokinetics and clinical utility of isavuconazole for treatment of invasive fungal infections
Joanne Livermore et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2012)
A new solid oral tablet formulation of posaconazole: a randomized clinical trial to investigate rising single- and multiple-dose pharmacokinetics and safety in healthy volunteers
G. Krishna et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2012)
Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010
Theo Vos et al.
LANCET (2012)
Amphotericin primarily kills yeast by simply binding ergosterol
Kaitlyn C. Gray et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Novel, unifying mechanism for amphotericin B and other polyene drugs: electron affinity, radicals, electron transfer, autoxidation, toxicity, and antifungal action.
Peter Kovacic et al.
MEDCHEMCOMM (2012)
Discovery of a Novel Class of Orally Active Antifungal β-1,3-D-Glucan Synthase Inhibitors
Scott S. Walker et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2011)
New Fks Hot Spot for Acquired Echinocandin Resistance in Saccharomyces cerevisiae and Its Contribution to Intrinsic Resistance of Scedosporium Species
Michael E. Johnson et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2011)
European guidelines for antifungal management in leukemia and hematopoietic stem cell transplant recipients: summary of the ECIL 3-2009 Update
J. Maertens et al.
BONE MARROW TRANSPLANTATION (2011)
Triazole Antifungal Agents in Invasive Fungal Infections A Comparative Review
Cornelia Lass-Floerl
DRUGS (2011)
Addressing current medical needs in invasive fungal infection prevention and treatment with new antifungal agents, strategies and formulations
Stuart K. Pitman et al.
EXPERT OPINION ON EMERGING DRUGS (2011)
Lack of Pharmacokinetic Drug Interaction Between Oral Posaconazole and Caspofungin or Micafungin
Gopal Krishna et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2011)
Caspofungin plus posaconazole as salvage therapy of invasive fungal infections in immunocompromised patients
Heinrich Lellek et al.
MYCOSES (2011)
Current Concepts in Antifungal Pharmacology
Russell E. Lewis
MAYO CLINIC PROCEEDINGS (2011)
PHARMACOLOGY AND METABOLISM OF ANIDULAFUNGIN, CASPOFUNGIN AND MICAFUNGIN IN THE TREATMENT OF INVASIVE CANDIDOSIS - REVIEW OF THE LITERATURE
G. Kofla et al.
EUROPEAN JOURNAL OF MEDICAL RESEARCH (2011)
Clinical Practice Guidelines for the Management of Cryptococcal Disease: 2010 Update by the Infectious Diseases Society of America
John R. Perfect et al.
CLINICAL INFECTIOUS DISEASES (2010)
Isavuconazole: A Comprehensive Review of Spectrum of Activity of a New Triazole
George R. Thompson et al.
MYCOPATHOLOGIA (2010)
Antifungal Therapeutic Drug Monitoring: Established and Emerging Indications
David Andes et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2009)
Clinical Practice Guidelines for the Management of Candidiasis: 2009 Update by the Infectious Diseases Society of America
Peter G. Pappas et al.
CLINICAL INFECTIOUS DISEASES (2009)
New generation azole antifungals in clinical investigation
Corrado Girmenia
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2009)
Antifungal drug resistance mechanisms
Javier Peman et al.
EXPERT REVIEW OF ANTI-INFECTIVE THERAPY (2009)
Treatment of aspergillosis: Clinical practice guidelines of the infectious diseases society of America
Thomas J. Walsh et al.
CLINICAL INFECTIOUS DISEASES (2008)
Clinical practice guidelines for the management of blastomycosis: 2008 update by the Infectious Diseases Society of America
Stanley W. Chapman et al.
CLINICAL INFECTIOUS DISEASES (2008)
Combination polyene-caspofungin treatment of rhino-orbital-cerebral mucormycosis
Caitlin Reed et al.
CLINICAL INFECTIOUS DISEASES (2008)
Resistance to antifungal agents: Mechanisms and clinical impact
Zeina A. Kanafani et al.
CLINICAL INFECTIOUS DISEASES (2008)
The Enzymatic Basis of Drug-Drug Interactions with Systemic Triazole Antifungals
Yasmine Nivoix et al.
CLINICAL PHARMACOKINETICS (2008)
Salvage therapy for invasive aspergillosis
D. H. Dockrell
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2007)
Posaconazole: A broad-spectrum triazole antifungal agent
Vijayalakshmi Nagappan et al.
CLINICAL INFECTIOUS DISEASES (2007)
Clinical practice guidelines for the management of patients with histoplasmosis: 2007 update by the infectious diseases society of America
L. Joseph Wheat et al.
CLINICAL INFECTIOUS DISEASES (2007)
Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia
Oliver A. Cornely et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: An externally controlled trial
Thomas J. Walsh et al.
CLINICAL INFECTIOUS DISEASES (2007)
Safety profile of concomitant use of caspofungin and cyclosporine or tacrolimus in liver transplant patients
F. Saner et al.
INFECTION (2006)
Long QTc interval and torsade de pointes caused by fluconazole
C. Phu Pharn et al.
ANNALS OF PHARMACOTHERAPY (2006)
Micafungin: A new echinocandin
PH Chandrasekar et al.
CLINICAL INFECTIOUS DISEASES (2006)
Combination therapy of disseminated coccidioidomycosis with caspofungin and fluconazole
DW Park et al.
BMC INFECTIOUS DISEASES (2006)
Pharmacokinetic and maximum tolerated dose study of micafungin in combination with fluconazole versus fluconazole alone for prophylaxis of fungal infections in adult patients undergoing a bone marrow or peripheral stem cell transplant
J Hiemenz et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2005)
History of the development of azole derivatives
JA Maertens
CLINICAL MICROBIOLOGY AND INFECTION (2004)
Successful treatment of coccidioidal meningitis with voriconazole
KJ Cortez et al.
CLINICAL INFECTIOUS DISEASES (2003)
Caspofungin: the first representative of a new antifungal class
V Letscher-Bru et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2003)
Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis
R Herbrecht et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Flucytosine: a review of its pharmacology, clinical indications, pharmacokinetics, toxicity and drug interactions
A Vermes et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2000)
分享论文
